|
|
| | N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,3-dimethylphenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Basic information |
| | N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,3-dimethylphenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Chemical Properties |
| Boiling point | 774.9±60.0 °C(Predicted) | | density | 1.406±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 5 mg/mL (9.76 mM; ultrasonic and warming and heat to 80°C) | | pka | 11.44±0.70(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,3-dimethylphenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Usage And Synthesis |
| Uses | RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC50 of 1.1 μM[1]. | | IC 50 | RIPK3: 9.1 nM (IC50) | | References | [1] Amy C Hart, et al. Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage. ACS Med Chem Lett. 2019 May 6;11(3):266-271. DOI:10.1021/acsmedchemlett.9b00065 |
| | N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,3-dimethylphenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Preparation Products And Raw materials |
|